Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares Acumen Pharmaceuticals and Voyager Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -58.24% | -46.53% |
| Voyager Therapeutics | -126.49% | -27.36% | -21.06% |
Valuation and Earnings
This table compares Acumen Pharmaceuticals and Voyager Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | N/A | N/A | -$102.33 million | ($1.94) | -0.77 |
| Voyager Therapeutics | $80.00 million | 2.24 | -$65.00 million | ($1.46) | -2.22 |
Voyager Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Acumen Pharmaceuticals has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Acumen Pharmaceuticals and Voyager Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Voyager Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
Acumen Pharmaceuticals currently has a consensus target price of $6.33, indicating a potential upside of 322.22%. Voyager Therapeutics has a consensus target price of $13.39, indicating a potential upside of 313.27%. Given Acumen Pharmaceuticals’ higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Voyager Therapeutics.
Institutional & Insider Ownership
71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Voyager Therapeutics beats Acumen Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
